share_log

HC Wainwright & Co. Reiterates Buy on Indaptus Therapeutics, Maintains $12 Price Target

HC Wainwright & Co. Reiterates Buy on Indaptus Therapeutics, Maintains $12 Price Target

HC Wainwright & Co.重申对Indaptus Therapeutics的买入,维持12美元的目标股价
Benzinga ·  2023/08/08 06:20

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Indaptus Therapeutics (NASDAQ:INDP) with a Buy and maintains $12 price target.

HC Wainwright&Co.分析师Raghuram Selvaraju重申Indaptus Treateutics(纳斯达克:INDP)的买入,并维持12美元的目标价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发